Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesGenetic & Molecular TestingUnivera Expanded Molecular Coverage | OpenPayer
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentUnivera HealthcarePolicy 2.02.62

    Expanded Molecular Testing for Infectious Disease Pathogens in the Outpatient Setting

    Customize your policy alerts

    Sign up for univerahealthcare Policy 2.02.62 alerts

    Get alerted when Policy 2.02.62 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs medical necessity for expanded molecular testing used to identify infectious disease pathogens in the outpatient setting. Coverage applies when acute infection symptoms are present, focused diagnostic testing has not identified a pathogen, testing will affect management, and the testing scope is clinically appropriate.

    Policy Summary
    PayerUnivera Healthcare
    PolicyExpanded Molecular Testing for Infectious Disease Pathogens in the Outpatient Setting
    Policy CodePolicy 2.02.62
    Change TypeNew policy
    Effective DateFeb 15, 2027
    Next Review DateOct 1, 2027
    Key ActionDocument the patient's clinical presentation, risk factors, suspected diagnosis, and how the selected test is expected to support meaningful clinical decision-making.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    4Indication-specific testing categories
    Age ≥ 65High-risk age criterion
    OutpatientRequired care setting
    All criteriaMedical-necessity framework

    Coverage Criteria

    General coverage requirements

    Covered when ALL of the following are met, including at least one qualifying indication-specific category.

    General medical-necessity requirements

    • Outpatient setting: The individual is in the outpatient setting.
    • Unidentified pathogen after focused evaluation: Initial focused diagnostic evaluation has not identified a causative pathogen, such as through sputum culture or urine culture.
    • Expected management impact: Testing results are expected to directly influence clinical management, such as antibiotic or antiviral selection, and avoid unnecessary treatment or additional testing.
    Policy Summary
    PayerUnivera Healthcare
    PolicyExpanded Molecular Testing for Infectious Disease Pathogens in the Outpatient Setting
    Policy CodePolicy 2.02.62
    Change TypeNew policy
    Effective DateFeb 15, 2027
    Next Review DateOct 1, 2027
    Key ActionDocument the patient's clinical presentation, risk factors, suspected diagnosis, and how the selected test is expected to support meaningful clinical decision-making.
    SourceLink
    On This Page
    Coverage CriteriaCovered IndicationsEligibility RequirementsNot CoveredCoding and Code SetsProvider Documentation and Action ItemsBackgroundDefinitions
    Reasonable pathogen scope: The number of pathogens tested does not exceed those reasonably necessary to evaluate the member's clinical presentation.
  1. Acute infection symptoms: The individual has signs and symptoms of acute infection.
  2. Qualifying testing category

    • Expanded respiratory pathogen testing: The respiratory pathogen testing criteria are met.
    • Expanded genitourinary/UTI testing: The genitourinary/UTI testing criteria are met.
    • Expanded sexually transmitted infection testing: The sexually transmitted infection testing criteria are met.
    • Expanded gastrointestinal pathogen testing: The gastrointestinal pathogen testing criteria are met.
  3. Expanded respiratory pathogen testing

    Expanded respiratory pathogen testing is covered when ANY of the following are met.

    Respiratory testing indication

    • Risk of hospitalization: The individual is being evaluated in the outpatient setting and is considered at risk for hospitalization due to illness severity.
    • High-risk individual: The individual is considered high risk.Age ≥ 65, immunocompromised, or significant comorbidities

    Expanded genitourinary/UTI testing

    Expanded genitourinary/UTI testing is covered when ANY of the following are met.

    Genitourinary/UTI testing indication

    • Risk of hospitalization: The individual is being evaluated in the outpatient setting and is considered at risk for hospitalization due to illness severity.
    • High-risk individual: The individual is considered high risk.Age ≥ 65, immunocompromised, or significant comorbidities
    • Complicated UTI: The individual has a complicated UTI, such as with a chronic indwelling catheter or ileal conduit.
    • Recurrent infection after failed empiric therapy: The individual has recurrent infections that have failed empiric therapy.

    Expanded sexually transmitted infection testing

    Expanded sexually transmitted infection testing is covered when ANY of the following are met.

    STI testing indication

    • Risk of hospitalization: The individual is being evaluated in the outpatient setting and is considered at risk for hospitalization due to illness severity.
    • High-risk status: Documentation supports that the individual is considered high risk.High-risk exposure, age ≥ 65, immunocompromised, or significant comorbidities
    • High-risk or symptomatic presentation: There is clinical concern due to a high-risk or symptomatic presentation requiring broad evaluation.

    Expanded gastrointestinal pathogen testing

    Expanded gastrointestinal pathogen testing is covered when ALL of the following are met.

    Gastrointestinal pathogen testing indication

    • Risk of hospitalization: The individual is being evaluated in the outpatient setting and is considered at risk for hospitalization due to illness severity.
    • High-risk individual: The individual is considered high risk.Age ≥ 65, immunocompromised, significant comorbidities, or travel outside of the country
    • Acute or persistent diarrhea with severe-disease risk: The individual has acute or persistent diarrhea and risk factors or signs of severe disease, such as bloody diarrhea, dysentery, dehydration, or severe abdominal pain.

    Expanded gastrointestinal pathogen testing

    Expanded gastrointestinal pathogen testing is covered when all of the following criteria are met.

    Gastrointestinal pathogen testing criteria

    • High-risk status: The individual is considered high risk.Age ≥ 65, immunocompromised, significant comorbidities, or travel outside of the country

      At least one listed high-risk factor supports this branch.

    • Clinical presentation: The individual has acute or persistent diarrhea and risk factors or signs of severe disease.Risk factors or severe-disease signs may include bloody diarrhea, dysentery, dehydration, or severe abdominal pain.

      Both diarrhea and supporting risk factors or severe-disease signs are required.

    Respiratory pathogen panels

    Expanded respiratory panels are supported when the clinical presentation or patient risk makes pathogen identification likely to alter management.

    Respiratory high-value circumstances: The patient has moderate-to-severe illness, elevated risk of deterioration, or is a high-risk host.High-risk status includes age ≥ 65, immunocompromise, or significant comorbidities.

    Routine multiplex use in mild or uncomplicated outpatient respiratory infection is not supported when patient-important outcomes are unlikely to improve.

    Genitourinary and urinary tract infection panels

    Expanded UTI panels may be considered for clinically complicated or refractory presentations.

    Urinary high-value circumstances: The patient is a high-risk host; has a complicated UTI, such as with a chronic indwelling catheter or ileal conduit; or has recurrent infection that has failed empiric therapy.Examples of complicated UTI include chronic indwelling catheter or ileal conduit.

    Not supported for uncomplicated cystitis or asymptomatic patients.

    Sexually transmitted infection panels

    Expanded STI panels are best reserved for presentations in which broad evaluation is clinically warranted.

    STI high-value circumstances: The patient is a high-risk host or has a symptomatic or otherwise high-risk presentation requiring broad evaluation, particularly when coinfection is likely or multiple pathogens need to be ruled out.Coinfection rates of 25% or more have been reported in high-risk groups.

    All detected organisms must be interpreted in clinical context, particularly organisms frequently found in asymptomatic individuals.

    Gastrointestinal pathogen panels

    Expanded gastrointestinal panels have greatest clinical value when illness severity, duration, risk, or comorbidity increases the likelihood that results will change management.

    Gastrointestinal high-value circumstances: The patient has severe symptoms, prolonged illness, an immunocompromising condition, significant comorbidities, or other features suggesting that results will meaningfully influence clinical management.

    Panels may detect colonizing organisms or pathogens associated with self-limited disease, which can lead to unnecessary treatment.

    Expanded molecular testing is not medically necessary for routine screening, duplicate or repeat panels during the same illness episode or before the appropriate retest interval, or initial evaluation when standard testing or culture is appropriate. It is also excluded for asymptomatic individuals without risk factors, mild self-limited symptoms, insufficiently documented clinical utility, or testing ordered solely for convenience or rapid turnaround time.

    Expanded UTI panels are not covered for uncomplicated cystitis or asymptomatic patients. Expanded urinary molecular testing is generally reserved for high-risk hosts, complicated UTI presentations, or recurrent infections that have failed empiric therapy.

    Routine broad respiratory panel testing is not supported for mild or uncomplicated outpatient respiratory illness when pathogen identification is unlikely to influence treatment or other patient-important outcomes.

    Listed codes may not be covered under all circumstances. Coverage remains subject to the applicable benefit and the policy’s medical-necessity criteria.

    Expanded molecular testing is not medically necessary when used for routine screening, duplicate or premature repeat testing, initial evaluation where standard testing or culture is appropriate, asymptomatic individuals without risk factors, or mild self-limited symptoms. It is also not supported when documentation does not establish clinical utility over a single-pathogen or smaller targeted test, or when convenience or rapid turnaround time is the only rationale.

    Routine expanded urinary molecular testing is not supported across all patient populations, particularly when detection of low-count organisms or urinary-microbiome organisms may represent colonization, asymptomatic bacteriuria, or organisms of uncertain clinical significance.

    Routine multiplex respiratory testing is not medically necessary for most immunocompetent outpatients when identifying a specific pathogen is unlikely to change treatment or other patient-important outcomes.

    Covered Indications

    Expanded molecular testing for infectious disease pathogen identification in qualifying outpatient presentations

    Coverage is available for expanded molecular testing for infectious disease pathogen identification when the general requirements and the applicable indication-specific criteria are satisfied.

    Qualifying outpatient presentation

    • Applicable indication-specific category

      • Respiratory pathogen testing: Respiratory testing criteria are met.
      • Genitourinary or UTI testing criteria are met.
      • STI testing criteria are met.
      • Gastrointestinal pathogen testing criteria are met.

    Infectious disease syndromes with multiple pathogens and comprehensive single-specimen evaluation

    Expanded testing may be medically necessary for infectious disease syndromes in which multiple pathogens can produce similar clinical manifestations and comprehensive identification from a single specimen is clinically important.

    Comprehensive single-specimen evaluation

    • Applicable infectious syndrome: The presentation involves a respiratory, gastrointestinal, central nervous system, bloodstream, or sexually transmitted infection syndrome.
    • Clinical necessity for broad evaluation: Rapid identification of polymicrobial infection is clinically critical or the results are expected to meaningfully influence management.

      Targeted single- or low-target assays, standard urine culture, or guideline-directed serology are expected when appropriate, particularly in urgent care or office settings.

    Syndromes involving bacterial, viral, fungal, parasitic, or antimicrobial-resistance targets

    Testing should be selected according to the clinical presentation, medical history, exposure risk, suspected diagnosis, and likelihood that results will influence management.

    Syndrome and target selection

    • Potential target type: The clinically relevant targets may be bacterial, viral, fungal, parasitic, or antimicrobial-resistance targets.
    • Clinical rationale: Selection of the test is supported by the patient's clinical presentation, medical history, exposure risk, suspected diagnosis, and the likelihood that results will support meaningful clinical decision-making.

    Eligibility Requirements

    Eligibility requires that the initial focused diagnostic evaluation has not identified a causative pathogen, such as through sputum culture or urine culture. The applicable general medical-necessity and indication-specific criteria must also be satisfied.

    Use targeted single- or low-target assays, standard urine culture, or guideline-directed serology when those tests are appropriate, particularly in urgent care or office settings. Expanded testing should be reserved for situations in which rapid identification of polymicrobial infection is clinically critical.

    No separate additional eligibility requirements are specified for routine urinary presentations. Expanded UTI testing may be considered for a high-risk host, complicated UTI such as one involving a chronic indwelling catheter or ileal conduit, or recurrent infection that has failed empiric therapy; it is not supported for uncomplicated cystitis or asymptomatic patients.

    Not Covered

    General non-covered uses include routine screening, duplicate or premature repeat panels, initial broad testing when standard testing or culture is appropriate, asymptomatic testing without risk factors, mild self-limited illness, testing without demonstrated clinical utility, and testing performed solely for convenience or rapid turnaround time.

    Expanded molecular UTI panels are not covered for uncomplicated cystitis or asymptomatic patients. Routine urinary molecular findings may reflect colonization or organisms of uncertain clinical significance rather than a condition requiring treatment.

    Coding and Code Sets

    CPT Codes: Vaginal and bacterial vaginosis/vaginitis molecular testingCPT
    81513Infectious disease, bacterial vaginosis, quantitative real-time amplification of RNA markers for Atopobium vaginae, Gardnerella vaginalis, and Lactobacillus species, utilizing vaginal-fluid specimens, algorithm reported as a positive or negative result for bacterial vaginosis.
    81514Infectious disease, bacterial vaginosis and vaginitis, quantitative real-time amplification of DNA markers for Gardnerella vaginalis, Atopobium vaginae, Megasphaera type 1, Bacterial Vaginosis Associated Bacteria-2 (BVAB-2), and Lactobacillus species (L. crispatus and L. jensenii), utilizing vaginal-fluid specimens, algorithm reported as positive or negative for high likelihood of bacterial vaginosis, including separate detection of Trichomonas vaginalis and/or Candida species, Candida glabrata, Candida krusei, when reported.
    81515Infectious disease, bacterial vaginosis and vaginitis, real-time PCR amplification of DNA markers for Atopobium vaginae, Atopobium species, Megasphaera type 1, and Bacterial Vaginosis Associated Bacteria-2 (BVAB-2), utilizing vaginal-fluid specimens, algorithm reported as positive or negative for high likelihood of bacterial vaginosis, including separate detection of Trichomonas vaginalis and Candida species, Candida glabrata/Candida krusei.
    CPT Codes: Gastrointestinal, respiratory, and multiple-organism molecular testingCPT
    87505Infectious agent detection by nucleic acid (DNA or RNA); gastrointestinal pathogen (e.g., Clostridium difficile, E. coli, Salmonella, Shigella, norovirus, Giardia), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 3–5 targets.
    87506Infectious agent detection by nucleic acid (DNA or RNA); gastrointestinal pathogen (e.g., Clostridium difficile, E. coli, Salmonella, Shigella, norovirus, Giardia), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 6–11 targets.
    87507Infectious agent detection by nucleic acid (DNA or RNA); gastrointestinal pathogen (e.g., Clostridium difficile, E. coli, Salmonella, Shigella, norovirus, Giardia), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 12–25 targets.
    87631Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus (e.g., adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus, respiratory syncytial virus, rhinovirus), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 3–5 targets.
    87632Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus, includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 6–11 targets.
    87633Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus, includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 12–25 targets.
    87800Infectious agent detection by nucleic acid (DNA or RNA), multiple organisms; direct probe(s) technique.
    87801Infectious agent detection by nucleic acid (DNA or RNA), multiple organisms; amplified probe(s) technique.
    CPT Codes: Proprietary laboratory analysesCPT
    0068UAmplified probe(s) technique Candida species panel (C. albicans, C. glabrata, C. parapsilosis, C. kruseii, C. tropicalis, and C. auris), amplified probe technique with qualitative report of the presence or absence of each species.
    0112UInfectious agent detection and identification, targeted sequence analysis (16S and 18S rRNA genes) with drug-resistance gene.
    CPT Codes: Proprietary respiratory and genitourinary molecular testsCPT
    0115URespiratory infectious agent detection by nucleic acid (DNA and RNA), 18 viral types and subtypes and 2 bacterial targets, amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected.
    0202UNucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected; infectious disease (bacterial or viral respiratory tract infection), pathogen-specific.
    0504UInfectious disease (urinary tract infection), identification of 17 pathologic organisms, urine, real-time PCR, reported as positive or negative for each organism.
    CPT Codes: Genitourinary and sexually transmitted infection molecular testsCPT
    0703UInfectious disease (urinary tract infection), identification of 21 pathogens, urine, real-time PCR with reflex to 22 antimicrobial-resistance genes when indicated, qualitative reporting for each organism. Effective 1/1/27.
    0704UInfectious disease (urinary tract infection and sexually transmitted infection), identification of 25 pathogens, urine, real-time PCR with reflex to 22 antimicrobial-resistance genes when indicated, qualitative reporting for each organism. Effective 1/1/27.
    0707UInfectious disease (urinary tract infection), identification of 27 bacterial and fungal pathogens, urine, real-time PCR, qualitative reporting for each organism. Effective 1/1/27.
    HCPCS CodesHCPCS
    Not ApplicableNot Applicable
    ICD-10 CodesICD-10
    Not ApplicableNot Applicable
    HCPCS Codes — Not ApplicableHCPCS
    No codes listed
    ICD-10 Codes — Not ApplicableICD-10
    No codes listed
    High-risk age criterion
    High-risk age thresholdAge ≥ 65
    Respiratory testingAge 65 or older is included as high-risk status
    Genitourinary, STI, and gastrointestinal testingAge 65 or older is included among high-risk factors
    Gastrointestinal multiplex panel target counts
    3–5 targetsGastrointestinal multiplex panel band
    6–11 targetsGastrointestinal multiplex panel band
    12–25 targetsGastrointestinal multiplex panel band
    Respiratory multiplex panel target counts
    3–5 targetsRespiratory multiplex panel band
    6–11 targetsRespiratory multiplex panel band
    12–25 targetsRespiratory multiplex panel band

    Provider Documentation and Action Items

    Documentation Required

    Document STI high-risk status

    For expanded STI testing, document that the individual is high risk, including high-risk exposure, age 65 or older, immunocompromised status, or significant comorbidities.

    Documentation Required

    Document clinical presentation and severity

    Document the symptomatic or high-risk presentation requiring broad evaluation, including clinical severity, symptoms, and relevant risk factors. For gastrointestinal testing, include severe disease signs or risk factors when present.

    Documentation Required

    Justify distinct same-day tests

    When individual and expanded molecular tests are requested on the same date of service, document the clinical rationale establishing that each test is separate and distinct from every other procedure performed that day.

    Documentation Required

    Support gastrointestinal testing criteria

    For expanded gastrointestinal pathogen testing, document high-risk status and acute or persistent diarrhea with risk factors or signs of severe disease, such as bloody diarrhea, dysentery, dehydration, or severe abdominal pain.

    Documentation Required

    Document same-day test distinction

    If individual and expanded molecular tests are ordered on the same date of service, explain why each test is separate and distinct from the other procedures performed that day.

    Documentation Required

    Document the rationale for test selection

    Document the patient's clinical presentation, risk factors, suspected diagnosis, and how the selected test is expected to support meaningful clinical decision-making.

    Denial Risk

    Meet general medical-necessity requirements

    Coverage may be denied when the member is not being evaluated in the outpatient setting, the initial focused diagnostic evaluation has identified a causative pathogen, results are not expected to directly influence clinical management, or the panel tests more pathogens than reasonably necessary for the presentation.

    Denial Risk

    Establish a qualifying indication

    Coverage may be denied when the member has no signs or symptoms of acute infection or does not meet the applicable indication-specific criteria for expanded respiratory, genitourinary/UTI, STI, or gastrointestinal pathogen testing.

    Denial Risk

    Avoid routine and duplicate broad testing

    Expanded molecular testing is not medically necessary for routine screening, duplicate or repeat panel testing during the same illness episode or before the appropriate retest interval, or initial evaluation when standard testing or culture is appropriate.

    Denial Risk

    Demonstrate clinical necessity and utility

    Testing is not medically necessary when the individual is asymptomatic without risk factors, symptoms are mild and self-limited, documentation does not establish clinical utility over a single-pathogen or smaller targeted test, or convenience or rapid turnaround time is the sole rationale.

    Step Therapy

    Use targeted or standard testing when appropriate

    Reserve expanded testing for settings where rapid identification of polymicrobial infections is critical. Use targeted single- or low-target assays, standard urine culture, or guideline-directed serology when appropriate, particularly in urgent care or office settings.

    Denial Risk

    Do not use expanded UTI panels for uncomplicated presentations

    Expanded UTI panels are excluded for uncomplicated cystitis and asymptomatic patients.

    Denial Risk

    Avoid routine broad respiratory testing

    Routine expanded respiratory panel testing is not supported for mild or uncomplicated outpatient respiratory presentations when results are unlikely to influence management.

    Denial Risk

    Avoid testing for colonization or uncertain findings

    Routine expanded urine molecular testing is not supported when detection of low-count or urinary-microbiome organisms may represent colonization or organisms of uncertain clinical significance.

    Denial Risk

    Interpret broad STI results clinically

    Broad STI panels may identify organisms such as Ureaplasma species or Mycoplasma hominis that commonly occur in asymptomatic individuals and may not require treatment. Interpret results in clinical context and reserve broad evaluation for clinically warranted presentations.

    Billing Rule

    Confirm coverage for the specific circumstance

    Codes may not be covered under all circumstances; confirm that the specific service is covered for the member's benefit and clinical circumstances.

    Billing Rule

    Use the laboratory-approved collection device

    For STI NAATs, use the manufacturer-specific collection and transport device recommended by the laboratory; otherwise, results may be compromised and specimens may be rejected.

    Background

    Expanded molecular pathogen testing is intended for outpatient evaluation of acute infectious syndromes after an initial focused diagnostic workup has not identified the causative pathogen. Results must be expected to influence management, such as antibiotic or antiviral selection, and testing should be limited to the pathogens reasonably necessary for the clinical presentation. The policy addresses respiratory, genitourinary/UTI, sexually transmitted infection, and gastrointestinal pathogen testing, with additional risk or severity criteria for each category.

    Definitions

    Expanded molecular testing
    Test methodMultiplex molecular assay
    ScopeEvaluates numerous pathogens associated with a clinical syndrome
    Specimen requirementUses a single patient specimen
    Targeted diagnostic testing
    PurposeDetect, identify, confirm, or rule out an infectious pathogen
    Diagnostic scopeA specific suspected infectious pathogen or a limited number of pathogens
    Selection basisClinical presentation, medical history, exposure risk, or other diagnostic information
    Targeted diagnostic testing
    Clinical useMost commonly used when clinical findings point to a likely diagnosis
    Diagnostic approachDirected toward a focused diagnostic hypothesis
    Available methodologiesMay use molecular, culture-based, antigen, serologic, or other laboratory methods
    Expanded molecular testing
    Test methodMultiplex molecular diagnostic assays
    Identification approachSimultaneously identifies multiple microorganisms associated with a clinical syndrome from a single specimen
    Potential targetsBacterial, viral, fungal, parasitic, and antimicrobial-resistance targets
    Diagnostic stewardship
    Core approachCoordinated selection, timing, performance, and interpretation of diagnostic tests
    Clinical purposeImprove patient outcomes and support appropriate clinical management
    Resource stewardshipReduce unnecessary testing, support antimicrobial stewardship, and optimize healthcare resources
    Laboratory-developed tests
    DefinitionTests developed and validated in-house and marketed as a laboratory service
    Regulatory standardMust meet the general regulatory standards of the Clinical Laboratory Improvement Amendments (CLIA)
    Laboratory licenseOffering laboratories must be licensed by CLIA for high-complexity testing
    Code designations
    E/IExperimental/Investigational
    NMNNot medically necessary/appropriate
    LocationDesignations are listed under CODE(S)